by New research published in the journal “Nature Communications” has identified a potential pathway that could lead to a reduction in breast cancer brain metastases. The study, conducted by researchers at the University of California, San Francisco (UCSF), focused on a specific protein called “EphA3” and its role in the development of brain metastases.
According to the researchers, EphA3 plays a crucial role in the process of breast cancer cells spreading to the brain. By blocking the activity of this protein, they were able to significantly reduce the number of breast cancer cells that were able to form tumors in the brains of mice.
The team used a Monoclonal Antibody Therapeutics to target and block the EphA3 protein, resulting in a 75% decrease in breast cancer brain metastases. The researchers believe that this approach could potentially be used in future treatments for breast cancer patients at risk of developing brain metastases.
The study’s lead author, Dr. Anand K. Swaroop, stated, “Our findings suggest that blocking EphA3 could be a promising strategy for preventing breast cancer brain metastases. We are now working to develop a clinical-grade version of the antibody for use in patients.”
The researchers also noted that this approach could potentially be used in combination with other treatments, such as chemotherapy or radiation, to further improve outcomes for breast cancer patients.
The study provides hope for those affected by breast cancer and offers a potential new avenue for research in the fight against this disease. Further studies are needed to confirm the effectiveness of this approach in humans and to explore its potential use in other types of cancer.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
